C.K. Cooper Reiterates Isoray Buy, $2 PT

by Hilary Farrell, Benzinga Staff Writer
July 12, 2011 10:27 AM | 23 seconds read |
C.K. Cooper & Company reiterated its Isoray ISR Buy rating and $2 price target in a research report published today. In the report, C.K. Cooper states, "IsoRay reported Q3-2011 and has issued a number of news releases over the past few months worth noting regarding Cesium use in the marketplace coupled with an expected GliaSite filing in the U.S." Shares of Isoray were trading at $1.41, up 27.03% from Monday's market close.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Analyst ColorReiterationAnalyst RatingsBiotechnologyC.K. Cooper & CompanyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!